Cargando…

Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date

Breast cancer remains the second leading cause of cancer mortality in women. Endocrine therapy is the backbone treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, the most common subtype. Although several endocrine therapy agents are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varella, Leticia, Cristofanilli, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041978/ https://www.ncbi.nlm.nih.gov/pubmed/36993871 http://dx.doi.org/10.2147/OTT.S400563

Ejemplares similares

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
por: Bardia, Aditya, et al.
Publicado: (2021)

Elacestrant: First Approval
por: Hoy, Sheridan M.
Publicado: (2023)

Elacestrant in metastatic breast cancer: Is the “standard of care” meeting standard requirements?
por: Olivier, Timothée, et al.
Publicado: (2021)

Modeling the novel SERD elacestrant in cultured fulvestrant-refractory HR-positive breast circulating tumor cells
por: Dubash, Taronish D., et al.
Publicado: (2023)

Advancing precision oncology in breast cancer: the FDA approval of elacestrant and Guardant360 CDx: a correspondence
por: Abbasi, Haleema Qayyum, et al.
Publicado: (2023)

Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
por: Patel, Hitisha K., et al.
Publicado: (2019)

Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer
por: Schlam, Ilana, et al.
Publicado: (2022)

Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2022)

Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
por: Hu, Taobo, et al.
Publicado: (2021)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer
por: Buus, Richard, et al.
Publicado: (2018)

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
por: Qing, Tao, et al.
Publicado: (2022)

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer
por: Bos, M. K., et al.
Publicado: (2023)

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer
por: Rigter, L S, et al.
Publicado: (2013)

Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer
por: Kim, Yun Yeong, et al.
Publicado: (2018)

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer
por: Ryu, Ho Hyun, et al.
Publicado: (2021)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Targeting estrogen to kill ER-positive and ER-negative breast cancer
por: Jordan, VC
Publicado: (2005)

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer
por: Bardia, Aditya, et al.
Publicado: (2022)

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
por: Bidard, Francois-Clement, et al.
Publicado: (2022)

Cryoablation In The Management Of Breast Cancer: Evidence To Date
por: Pusceddu, Claudio, et al.
Publicado: (2019)

COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer
por: Glynn, Sharon A, et al.
Publicado: (2010)

Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer
por: Loo, Claudette E., et al.
Publicado: (2016)

Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
por: Constantinidou, Anastasia, et al.
Publicado: (2022)

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
por: Zhang, Shaohua, et al.
Publicado: (2016)

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape
por: Xie, Peiling, et al.
Publicado: (2021)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

New Agents for the Management of Advanced HER2-Positive Breast Cancer
por: Royce, Melanie, et al.
Publicado: (2016)

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection
por: Cani, Andi K., et al.
Publicado: (2021)

Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012)

HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
por: Batra, Atul, et al.
Publicado: (2020)

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
por: Poorvu, Philip D., et al.
Publicado: (2020)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands
por: Miquel-Cases, Anna, et al.
Publicado: (2016)

Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2017)

First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer
por: Ettl, Johannes, et al.
Publicado: (2020)

Altona Prognostic Index: A New Prognostic Index for ER-Positive and Her2-Negative Breast Cancer of No Special Type
por: Wegscheider, Anne-Sophie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o7v7p1m79sg3umpbmq9rt31hsq